What you will learn

This conversation practices manual muscle testing using simple and clear English commands for neurological examination.

Key words

Neck flexors, Neck extensors, Deltoid, Biceps brachii, Triceps brachii, Wrist extensors, Wrist flexors, Pinch, Abductor pollicis brevis, First dorsal interosseous, Abductor digiti minimi, Flexor digitorum profundus, Iliopsoas, Rectus femoris, Hamstrings, Tibialis anterior, Gastrocnemius

Source

Clinical neurological examination (standard practice)

Note

This conversation is for educational purposes only.

What you will learn

This conversation introduces a step-by-step cranial nerve examination and helps you practice simple and practical English commands used in neurological exams.

Key words

Olfactory nerve. Optic nerve. Oculomotor nerve. Trochlear nerve. Trigeminal nerve. Abducens nerve. Facial nerve. Vestibulocochlear nerve. Glossopharyngeal nerve. Vagus nerve. Accessory nerve. Hypoglossal nerve.

Source

Clinical neurological examination (standard clinical practice).

Note

This conversation is for educational purposes only.

What you will learn

This episode reviews a multicenter retrospective study on cancer-associated stroke and explains why post-treatment plasma D-dimer levels, rather than pre-treatment levels, are independently associated with poor short-term outcomes and mortality.

Key words

Cancer-associated stroke.

Hypercoagulability.

Recurrent.

Cumulative.

Mortality rate.

Adjusted odds ratio.

Anticoagulation therapy.

Source

Post-Treatment Plasma D-Dimer Levels Are Associated With Short-Term Outcomes in Patients With Cancer-Associated Stroke.

Front. Neurol.2022;13:868137.

DOI:10.3389/fneur.2022.868137

Note

This episode isfor educational purposes only. This is a summary and commentary, not theoriginal article.

Episode 7, Stroke 1.

What you will learn

This episode reviews a multicentre retrospective study of corticosteroidtreatment in CIDP and explains that daily prednisolone, pulsed dexamethasone,and pulsed intravenous methylprednisolone showed broadly similar efficacy andsafety outcomes.

Key words
Pulsed dexamethasone.
Pulsed intravenous methylprednisolone.
Remission rates.
Cumulative steroid dose.
Responder.

Source
van Lieverloo GGA, Peric S, Doneddu PE, et al. Corticosteroids in chronicinflammatory demyelinating polyneuropathy: A retrospective, multicentre study,comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, andpulsed intravenous methylprednisolone. J Neurol. 2018;265:2052–2059. DOI:10.1007/s00415-018-8948-y.

Note
This episode is for educational purposes only. This is a summary andcommentary, not the original article.

Episode 6, CIDP 3.

What you will learn
This episode reviews a multicentre UK study on very high dose immunoglobulin treatment in CIDP and explains why dose escalation may not always be the best option in patients with a poor response.

Key wordsPre-treatment disability.Maximal improvement.Thromboembolic complications.Suboptimal response.

dose escalation. 

SourceVery High Dose Immunoglobulin Treatment for Chronic Inflammatory DemyelinatingPolyneuropathy: A Multicentre UK Study.
Eur J Neurol. 2025;32(11):e70429.
DOI: 10.1111/ene.70429.

NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.Episode 5, CIDP 2.

What you will learn
This episode reviews a multicenter study on chronic inflammatory demyelinating polyradiculoneuropathy, or CIDP, and explains how early treatment may be a key modifiable factor in reducing long-term disability.

Key wordsdeterminants, therapeutic factors, long-term disability, univariate and multivariate linear regression analyses, modifiable factor

SourceDeterminants of long-term disability in chronic inflammatory demyelinating polyradiculoneuropathy: A multicenter Korea/UK study of 144 patients.
Eur J Neurol. 2025;32(1):e16575.DOI: 10.1111/ene.16575

NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.

Episode 4, CIDP 1

What you will learnA short review of a serious case report involving lecanemab, t-PA, and multiple cerebral hemorrhages after acute ischemic stroke.Key words

cerebral hemorrhage, t-PA, homozygous, gaze preference, administer, intraparenchymal, cerebral amyloid angiopathySource
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
N Engl J Med. 2023;388:478-479.DOI: 10.1056/NEJMc2215148NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.

Episode 3, dementia 3

What you will learn
A short review of the TRAILBLAZER-ALZ 2 trial and how donanemab showed clinical benefit in early symptomatic Alzheimer’s disease.

Key words

• early symptomatic Alzheimer’s disease

• iADRS
• least-squares mean change
• CDR-SB
• amyloid plaque
• ARIA

Short summary
This episode reviews the TRAILBLAZER-ALZ 2 trial, published in JAMA in 2023. Donanemab slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Unlike Clarity AD, the pivotal trial of lecanemab, this study incorporated tau pathology into the trial design. The results supported the clinical benefit of anti-amyloid therapy, while adverse events such as amyloid-related imaging abnormalities remained important.

Source

Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023.

DOI: 10.1001/jama.2023.13239

Note

This episode is for educational purposes only. This is a summary and commentary, not the original article.

Episode 2. Dementia 2

What you will learn

A short review of a key paper in neurology, explained in simple English.

Key words

• monoclonal antibody

• protofibril

• cognitive decline

• CDR-SB

• ADAS-Cog14

• adjusted mean change

• adverse events

Short summary

Lecanemab slowed cognitive and functional decline in early Alzheimer’s disease over 18 months. Clinical outcomes such as CDR-SB and ADAS-Cog14 also favored lecanemab, although adverse events remained important.

Source

van Dyck CH, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023.

DOI: 10.1056/NEJMoa2212948

Note

This episode is for educational purposes only. This is a summary and commentary, not the original article.

Episode 1, Dementia 1